louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06037941: Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma
Official title: Breathprinting (E-Nose) Technology to Measure Response to Treatment of Malignant Pleural Mesothelioma (MPM) Through MPM-Specific Volatile Organic Compounds Detected in Exhalates
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Malignant Pleural Mesothelioma
Keywords: Breathprinting (E-Nose) Technology
MPM-Specific Volatile Organic Compounds
23-100
Lead sponsor: Memorial Sloan Kettering Cancer Center
Sponsor class: OTHER
Collaborators: name: UNIVERSITY CAMPUS BIO-MEDICO, ITALY
First posted: 2023-09-14
Enrollment: 20
Sex: ALL
Minimum age (years): 30
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The researchers are doing this study to test the ability of a new technology called breathprinting, or electronic nose (E-Nose), to measure how people respond to standard treatment for malignant pleural mesothelioma (MPM). The researchers will study how E-Nose breathprints change over time as people receive standard treatment for MPM. They will also look at how changes in people's E-Nose breathprints compare to changes in their standard imaging scans and in biomarkers of MPM in their blood.


Eligibility criteria: Inclusion Criteria:

* Aged 30-85 years
* No history of thoracic cancer or extrathoracic cancer potentially involving pleural metastases (i.e., breast, gastric, colon, or pancreas cancer)
* Recent diagnosis of MPM
* Documented, signed, and dated informed consent, obtained before any procedures, for the proposed research study, and signed standard surgical consent for surgical resection

Exclusion Criteria:

* Aged \<30 or \>85 years at the first outpatient visit
* History of thoracic or extrathoracic cancer that puts the subject at risk for pleural or pulmonary metastases

Primary outcomes:
measure: Change of MPMspecific VOCs
timeFrame: up to 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Basking Ridge
country: United States
facility: Memorial Sloan Kettering Basking Ridge (Consent Only)
state: New Jersey
city: Middletown
country: United States
facility: Memorial Sloan Kettering Monmouth (Consent Only)
state: New Jersey
city: Montvale
country: United States
facility: Memorial Sloan Kettering Bergen (Consent Only )
state: New Jersey
city: Commack
country: United States
facility: Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Consent Only)
state: New York
city: Harrison
country: United States
facility: Memorial Sloan Kettering Westchester (Consent Only)
state: New York
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center (All Protocol Activities)
state: New York
city: Uniondale
country: United States
facility: Memorial Sloan Kettering Nassau (Consent Only)
state: New York
Study officials:
affiliation: Memorial Sloan Kettering Cancer Center
name: Gaetano Rocco, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00693641: Efficiency of a Jellyfish Sting Inhibitor Sun Lotion and Protocols for Jellyfish Sting Pain Relief
Official title: Efficiency of a Jellyfish Sting Inhibitor Sun Lotion and Protocols for Jellyfish Sting Pain Relief
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Pain
Keywords: Jellyfish
Cyanea sp
Safe Sea
Prevention
treatment
Pain relief
Prevention of pain
Lead sponsor: University of Oslo
Sponsor class: OTHER
First posted: 2008-06-09
Enrollment: 39
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: The purpose of the study is to investigate the effectiveness of a sun lotion containing a specific Jellyfish sting inhibitor versus regular sun lotions as controls. In addition, to investigate the effectiveness of hot/cold immersion for the treatment of Cyanea sp stings versus local pain relief with prescription free pharmaceutical drug (Xylocain 30 mg/ml (3%) lidocain).


Eligibility criteria: Inclusion Criteria:

* Volunteers
* men or women
* aged 18 or over

Exclusion Criteria:

* People with atopic diseases, e.g., asthma, allergic rhinorrhea or rhinitis, hay fever, or atopic skin inflammation
* People who suffer from skin diseases in the testing regions or whose inner forearms are too hairy to allow for interpretation of the test
* People who have used any medical or cosmetic product on either arm for 48 hours before the start of the experiment
* People who are taking antihistamines or steroids
* Subjects with medical conditions which, in the opinion of the investigator, pose risks that would prohibit participating
* Subjects with a history of keloid formation will be excluded from the Jellyfish protocol
* Subjects with allergy to lidocain or other local pain substances

If the arms contain hair that might reduce the jellyfish tentacle contact with the skin, the arm must be shaved in advance, so the skin has no sign of piling or any skin damage before the test.

Primary outcomes:
measure: The purpose of the study is to investigate the effectiveness of a sun lotion containing a specific Jellyfish sting inhibitor versus regular sun lotions or no protection at all when in contact with Cyanea SP.
timeFrame: Repeated jellyfish contact for total of 240 second or until pain occurs
Secondary outcomes:
measure: Investigate the effectiveness of hot/cold immersion for the treatment of Cyanea sp stings versus local pain relief with prescription free pharmaceutical drugs called Xylocain with lidocaine
timeFrame: Pain relief treatment will start after 10 minutes, repeat treatment after 30 minutes if VAS score > 10.
Other outcomes:
Locations:
city: Biologveien 2
country: Norway
facility: University of Oslo, Biologisk Stasjon Drøbak
state: Drøbak
Study officials:
affiliation: University of Oslo, Biologisk Stasjon Drøbak
name: Hans Erik Karlsen, Associate prof.
role: STUDY_DIRECTOR
References:
Clinical trial NCT06945341: International Focus Group Discussion on Neuromuscular Monitoring.
Official title: International Focus Group-based Discussion on Factors Facilitating an Increased Adoption of Neuromuscular Monitoring.
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Anesthesia
Neuromuscular Blockade
Neuromuscular Block, Residual
Perioperative/Postoperative Complications
Anaesthesiology Devices Associated With Adverse Incidents, Diagnostic and Monitoring Devices
Lead sponsor: Universitair Ziekenhuis Brussel
Sponsor class: OTHER
Collaborators: name: AZ Sint-Jan AV
First posted: 2025-04-25
Enrollment: 16
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Active EU Anaesthesiologists

Brief summary: Focus-Group based discussion designed to gain more in-depth information on factors that could lead to an increase in the adoption of neuromuscular monitoring taking into account different country-specific contexts.


Eligibility criteria: Active EU Anaesthesiologists

Primary outcomes:
measure: Thematic analysis
timeFrame: 90 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Brugge
country: Belgium
facility: AZ Sint Jan
state: WV
Study officials:
References:
Clinical trial NCT03967041: Sarcopaenia is a Useful Risk Stratification Tool for Surgeons to Prognosticate Splenic Abscess Patients
Official title: Sarcopaenia is a Useful Risk Stratification Tool for Surgeons to Prognosticate Splenic Abscess Patients- A Retrospective Case Control Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Splenic Abscess
Sarcopenia
Keywords: splenic abscess
sarcopenia
surgical emergency
Lead sponsor: Chang Gung Memorial Hospital
Sponsor class: OTHER
First posted: 2019-05-30
Enrollment: 99
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: the patients visited emergency department with the diagnosis of splenic abscess

Brief summary: Sarcopaenia is associated with poor prognoses of in-hospital mortality in splenic abscess patients. Investigators recommend its use by surgeons in the ED to rapidly risk stratify and identify patients requiring urgent and aggressive intervention, to maximise patient outcomes and survival chances.

Detailed description: Splenic abscess is a life-threatening surgical emergency which requires early diagnosis and intervention to maximise patient outcomes. This can be achieved through accurate risk stratification in the emergency department (ED). Sarcopaenia refers to an age-related loss of skeletal muscle mass and strength with major physiologic and clinical ramifications. This study evaluates sarcopaenia as a radiological risk stratification tool to predict in-hospital mortality of splenic abscess patients.

99 adult patients at four training and research hospitals who had undergone abdominal contrast CT scans in the ED with the final diagnosis of splenic abscess from January 2005 to December 2015 were recruited. Evaluation for sarcopaenia was performed via calculating psoas cross-sectional area at level of L3 and normalising for height. Univariate analyses were used to evaluate the differences between survivors and non-survivors, with subsequent logistic regression analysis to assess odds ratio of sarcopaenia with respect to in-hospital mortality. A receiver operating characteristic (ROC) curve was plotted to determine predictability of sarcopaenia, with its corresponding sensitivity, specificity, and accuracy rate calculated.

Eligibility criteria: Inclusion Criteria:

All adult patients older than 20 years of age admitted to the aforementioned hospitals who had undergone an abdominal contrast CT scan in the ED with the final diagnosis of splenic abscess from January 2005 to December 2015

Exclusion Criteria:

Patients who could not be assessed for sarcopaenia in line with our study methodology and/or had other coexisting infections were excluded. Patients with abscesses involving the psoas muscles were also excluded.

Primary outcomes:
measure: Mortality
timeFrame: Up to 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Taoyuan
country: Taiwan
facility: Chang Gung Memorial Hospital
Study officials:
References:
Clinical trial NCT03652441: Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma
Official title: Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Classical Hodgkin Lymphoma
Lead sponsor: University of Cologne
Sponsor class: OTHER
First posted: 2018-08-29
Enrollment: 21
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The aim of the trial is to improve disease control after an allogeneic stem cell transplantation (alloSCT) for relapsed or refractory classical Hodgkin lymphoma (rrHL, cHL) with consolidation therapy by Brentuximab Vedotin (BV) for up to one year.

The primary objective of the trial is to show efficacy of the experimental consolidative treatment strategy. Secondary objectives are to further evaluate efficacy, show safety and feasibility and perform correlative studies.


Eligibility criteria: Inclusion Criteria:

* Patients with relapsed/refractory cHL who receive an allogeneic stem cell transplantation
* Histologically proven cHL in the most recent tumor biopsy
* Absolute neutrophil count ≥ 500/mm³
* ECOG ≤2
* Age ≥ 18 years

Exclusion Criteria:

* Presence of nodular lymphocyte-predominant HL (NLPHL) or grey-zone lymphoma
* Progressive disease as last documented response prior to alloSCT
* Any peripheral neuropathy ≥ grade 2
* Any other serious disease or organ dysfunction which might impair protocol treatment

Primary outcomes:
measure: 1-year Cumulative incidence of relapse (CIR)
timeFrame: 1 year
Secondary outcomes:
measure: 1- and 2-year Progression-free survival (PFS)
timeFrame: 1 and 2 years
Other outcomes:
Locations:
city: Cologne
country: Germany
facility: 1st Department of Medicine, Cologne University Hospital
Study officials:
affiliation: University of Cologne, I. Dept. of Medicine
name: Christof Scheid, Prof.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04984941: Evaluation of the Role of IgE Responses to Der p 1 and Der p 2 in Chinese House Dust Mite-Allergic Patients
Official title: Evaluation of the Role of IgE Responses to Der p 1 and Der p 2 in Chinese House Dust Mite-Allergic Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Asthma
Allergic Rhinitis
Conjunctivitis
Atopic Dermatitis
Keywords: House dust mite
Der p 1
Der p 2
China
Lead sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Sponsor class: OTHER
First posted: 2021-08-02
Enrollment: 100
Sex: ALL
Minimum age (years): 3
Maximum age (years): 60
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients were evaluated by a physician face-to-face, using a detailed questionnaire to establish the nature and severity of their clinical manifestations. The questionnaire also included demographic characteristics, a family history of allergic diseases and any other history of allergic disease.

Brief summary: One hundred patients were enrolled, based on sensitization and doctor-diagnosed allergy to HDM. Questionnaires were administered to document demographic and clinical characteristics. Serum IgE reactivity toDermatophagoides pteronyssinus (Dp) extract, Der p 1, Der p 2 and Der p 10 was measured by ImmunoCAP.

Detailed description: Background: The role of specific IgE (sIgE) against Der p 1and Der p 2 in Chinese patients with house dust mite (HDM)allergy has not yet been well investigated.Methods: One hundred patients were enrolled, based on sensitization and doctor-diagnosed allergy to HDM. Questionnaires were administered to document demographic and clinical characteristics. Serum IgE reactivity toDermatophagoides pteronyssinus (Dp) extract, Der p 1, Der p 2 and Der p 10 was measured by ImmunoCAP.

Eligibility criteria: Inclusion Criteria:

* HDM-allergic patients reporting allergic rhinitis, conjunctivitis, asthma and/or atopic dermatitis and who had never undergone immunotherapy, were enrolled if they were sensitized to Dp as judged by ImmunoCAP ( ≥ 1 kU/l) and/or skin reaction index (SRI)by skin-prick test (SPT, a wheal diameter ≥ 0.5 mm).

Exclusion Criteria:

* Patients who refused to participate in the study.

Primary outcomes:
measure: Demographic Characteristics
timeFrame: 1 year
measure: Der p 1 Serum IgE
timeFrame: 1 year
measure: Der p 2 Serum IgE
timeFrame: 1 year
measure: Dp, Der p 1 and Der p 2
timeFrame: 1 year
measure: Factors associated with specific IgE against Der p 1
timeFrame: 1 year
measure: Factors associated with specific IgE against Der p 2
timeFrame: 1 year
measure: the Number of Affected Organs
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Hangzhou
country: China
facility: Second Affiliated Hospital，School of Medicine，Zhejiang University
state: Zhejiang
Study officials:
affiliation: 2nd affiliated Hospital,School of Medicine,Zhejiang University,China
name: Wang Huiying
role: STUDY_CHAIR
References:
Clinical trial NCT02453841: Prospective Hemodynamic and Pharmacokinetic Analysis of Oxymetazoline Absorption
Official title: Prospective Hemodynamic and Pharmacokinetic Analysis of Oxymetazoline Absorption During Functional Endoscopic or Turbinate Reduction Surgery or Adenoidectomy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Adenoidectomy
Functional Endoscopic Sinus Surgery (FESS)
Turbinate Surgery
Lead sponsor: Nationwide Children's Hospital
Sponsor class: OTHER
First posted: 2015-05-27
Enrollment: 30
Sex: ALL
Minimum age (years): 2
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This proposed study will assess the hemodynamic effects and measure the systemic absorption of topically applied oxymetazoline in patients undergoing functional endoscopic sinus surgery, turbinate surgery, or adenoidectomy. These patients will be receiving oxymetazoline as standard of care during the surgery.


Eligibility criteria: Inclusion Criteria:

* Patients that are scheduled for:

  1. Functional endoscopic sinus surgery
  2. Turbinate reduction (with or without tonsillectomy and/or adenoidectomy)
  3. Adenoidectomy

Exclusion Criteria:

* Been treated with oral decongestants or antihistamines within 24 hours of surgery
* Are taking anticoagulants
* Have a history of nasal trauma
* Have a history of epistaxis
* Have a history of hypertension or cardiac disease
* Allergy to oxymetazoline

Primary outcomes:
measure: Blood Pressure Following Oxymetazoline Administration
timeFrame: 5 - 150 mins. after administration
measure: Heart Rate Following Oxymetazoline Administration.
timeFrame: 5 - 150 mins. after administration
Secondary outcomes:
measure: Ease of Hemostasis
timeFrame: intraoperative
measure: Amount of Bleeding
timeFrame: intraoperative
Other outcomes:
Locations:
city: Columbus
country: United States
facility: Nationwide Children's Hospital
state: Ohio
Study officials:
affiliation: Nationwide Children's Hospital
name: Richard Cartabuke, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01846234: Sodium Intake in Multiple Sclerosis
Official title: Effect of Sodium Intake in Multiple Sclerosis Disease Activity
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Multiple Sclerosis
Keywords: Multiple Sclerosis
Salt
Lead sponsor: Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia
Sponsor class: OTHER
First posted: 2013-05-03
Enrollment: 132
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: A total of 70 patients with relapsing-remitting MS according to McDonald criteria1 were recruited from the MS clinic at FLENI by attending neurologists. A second group of 52 relapsing-remitting MS patients was recluted later.

Brief summary: Recently, it has been shown that salt (ClNa, sodium chloride) can modulate the differentiation of human and mouse TH17 cells. Indeed, mice feed with high sodium diet were described to develop more aggressive course of EAE (Experimental Autoimmune Encephalitis).

However, the role of sodium intake in MS has not been investigated. In this study we investigate the effect of sodium intake in Multiple Sclerosis (MS) clinical and radiological activity.


Eligibility criteria: Inclusion Criteria:

* Subject is between 18 and 50 years old
* Subject has diagnosis of relapsing-remitting MS according to McDonald criteria (2010)

Exclusion Criteria:

* Patient who had hyponatremia in the last 90 days

Primary outcomes:
measure: Exacerbation rate
timeFrame: 2 years
Secondary outcomes:
measure: Radiological activity
timeFrame: One year
Other outcomes:
Locations:
city: Buenos Aires
country: Argentina
facility: FLENI
Study officials:
affiliation: Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia
name: Mauricio F Farez, MD MPH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05262634: Pregnancy Outcome in Women With an Iron Deficiency in the First Trimester
Official title: Pregnancy Outcome in Women With an Iron Deficiency in the First Trimester
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Iron Deficiency
Keywords: iron deficiency anemia of pregnancy
pregnancy outcome
perinatal risk
maternal risk
Lead sponsor: University Hospital, Basel, Switzerland
Sponsor class: OTHER
First posted: 2022-03-02
Enrollment: 713
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: The data comes from the patient files of pregnant women who were treated in the Polyclinic Women's Clinic University Hospital Basel between 2017 and 2019.

Brief summary: The primary aim of this retrospective, monocentric study with two parallel groups is to investigate pregnancy outcome in women with iron deficiency in the first trimester. It compares the pregnancy outcome between pregnant women with an iron deficiency and those without an iron deficiency in the first trimester. The study group are pregnant women with a diagnosed iron deficiency in the first trimester, a total of 227 pregnant women. The control group consists of 486 pregnant women without first-trimester iron deficiency. Matching criteria include parity and maternal age. Data from patient files of pregnant women who were treated in the Women's Clinic, University Hospital Basel between 2017 and 2019 are analyzed.


Eligibility criteria: Inclusion Criteria:

* Pregnant women with a documented iron deficiency in the first trimester
* Pregnant women with normal hematological parameters and iron status in the first trimester
* Treated at the Women's Clinic, University Hospital in Basel

Exclusion Criteria:

* Pregnant women with a documented rejection

Primary outcomes:
measure: Proportion of anemia
timeFrame: one time assessment at baseline
measure: Proportion of hemorrhage
timeFrame: one time assessment at baseline
measure: Proportion of growth retardation
timeFrame: one time assessment at baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Basel
country: Switzerland
facility: Women's Clinic, University Hospital Basel
Study officials:
affiliation: Women's Clinic, University Hospital Basel
name: Irene Hoesli, Prof. Dr. med.
role: STUDY_DIRECTOR
affiliation: Women's Clinic, University Hospital Basel
name: Gabriela Amstad Bencaiova, Dr. med.
role: PRINCIPAL_INVESTIGATOR
References: